ADMA BIOLOGICS, INC. ADMA

Latest FY: 2025 Healthcare Biotechnology
Market Price $9.39
Market Cap $2.18B
P/E Ratio 15.65
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑19.6% YoY
$510.17M
3-Yr CAGR: 49.0%
Net Income ↓-25.7% YoY
$146.93M
Net Margin: 28.8%
Free Cash Flow ↓-74.8% YoY
$27.82M
FCF Yield: 1.28%
EPS (Diluted) ↓-25.9% YoY
$0.60
Basic: $0.62
Return on Equity Efficiency
30.8%
ROA: 23.5%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (ADMA)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $10.5M $4.3M $-19.5M $-1.61 0.00% $-18.3M $-18.3M
FY 2017 $15.6M +48.5% $-6.4M $-43.8M -124.2% $-1.91 -18.6% 0.00% $-37.3M $-39.9M -117.8%
FY 2018 $17.0M +8.8% $-25.2M $-65.7M -50.2% $-1.45 +24.1% 0.00% $-62.7M $-64.8M -62.1%
FY 2019 $29.3M +72.8% $-10.2M $-48.3M +26.6% $-0.89 +38.6% 0.00% $-76.2M $-80.0M -23.5%
FY 2020 $42.2M +43.9% $-19.1M $-75.7M -56.9% $-0.88 +1.1% 0.00% $-102.0M $-114.7M -43.4%
FY 2021 $80.9M +91.7% $1.2M $-71.6M +5.4% $-0.51 +42.0% 0.00% $-112.4M $-125.9M -9.7%
FY 2022 $154.1M +90.4% $35.3M $-65.9M +8.0% $-0.33 +35.3% 0.00% $-59.5M $-73.4M +41.7%
FY 2023 $258.2M +67.6% $88.9M $-28.2M +57.2% $-0.13 +60.6% 0.00% $8.8M $4.0M +105.5%
FY 2024 $426.5M +65.2% $219.6M $197.7M +800.0% $0.81 +723.1% 0.00% $118.7M $110.4M +2,641.3%
FY 2025 $510.2M +19.6% $292.8M $146.9M -25.7% $0.60 -25.9% 0.00% $50.4M $27.8M -74.8%
$

Valuation

Market Price $9.39
Market Cap $2.18B
Enterprise Value $2.16B
P/E Ratio 15.65
P/B Ratio 4.56
FCF Yield 1.28%
Dividend Yield N/A
Shares Outstanding 231,772,700
%

Profitability & Margins

Gross Margin 57.39%
Operating Margin 37.53%
Net Margin 28.80%
Return on Equity (ROE) 30.78%
Return on Assets (ROA) 23.54%
Asset Turnover 0.82x
Revenue 3-Yr CAGR 49.05%
🛡️

Financial Health & Liquidity

Current Ratio 6.71
Cash Ratio 1.26
Debt / Equity 0.151
Debt / Assets 0.116
Cash & Equivalents $87.63M
Total Debt $72.14M
Book Value / Share $2.06
💧

Cash Flow Efficiency

Operating Cash Flow $50.40M
Capital Expenditures (CapEx) $22.57M
Free Cash Flow $27.82M
OCF / Revenue 9.88%
FCF / Revenue 5.45%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $0.60
EPS (Basic) $0.62
Dividends / Share N/A
Book Value / Share $2.06
EPS YoY Growth -25.93%
🏛️

Balance Sheet (FY 2025)

Total Assets $624.24M
Total Liabilities $146.92M
Stockholders' Equity $477.32M
Current Assets $466.51M
Current Liabilities $69.54M